A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
23 Jun 2020
Historique:
received: 30 05 2020
revised: 20 06 2020
accepted: 20 06 2020
entrez: 27 6 2020
pubmed: 27 6 2020
medline: 23 3 2021
Statut: epublish

Résumé

There is currently no effective long-term treatment for ovarian cancer (OC) resistant to poly-chemotherapy regimens based on platinum drugs. Preclinical and clinical studies have demonstrated a strong association between development of Pt-drug resistance and increased thymidylate synthase (hTS) expression, and the consequent cross-resistance to the hTS inhibitors 5-fluorouracil (5-FU) and raltitrexed (RTX). In the present work, we propose a new tool to combat drug resistance. We propose to treat OC cell lines, both Pt-sensitive and -resistant, with dual combinations of one of the four chemotherapeutic agents that are widely used in the clinic, and the new peptide, hTS inhibitor, [D-Gln

Identifiants

pubmed: 32585842
pii: ijms21124452
doi: 10.3390/ijms21124452
pmc: PMC7352236
pii:
doi:

Substances chimiques

Antimetabolites, Antineoplastic 0
Enzyme Inhibitors 0
Liposomes 0
Peptide Fragments 0
Quinazolines 0
Thiophenes 0
Polyethylene Glycols 3WJQ0SDW1A
Thymidylate Synthase EC 2.1.1.45
raltitrexed FCB9EGG971
Fluorouracil U3P01618RT

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG 10474
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG 16977

Références

Am J Clin Oncol. 2011 Aug;34(4):401-5
pubmed: 21791984
Jpn J Cancer Res. 2001 Jan;92(1):74-82
pubmed: 11173547
Cancer Res. 1991 Oct 15;51(20):5579-86
pubmed: 1913676
Eur J Pharmacol. 2009 Aug 1;615(1-3):17-26
pubmed: 19446547
Cancer Chemother Biol Response Modif. 2002;20:1-36
pubmed: 12703198
Clin Cancer Res. 2003 Feb;9(2):792-801
pubmed: 12576452
Cancer Res. 2005 Aug 1;65(15):6789-800
pubmed: 16061661
J Med Chem. 2012 Nov 26;55(22):10272-6
pubmed: 23075414
Clin Cancer Res. 2003 Mar;9(3):1171-8
pubmed: 12631623
Jpn J Cancer Res. 2000 Apr;91(4):424-32
pubmed: 10804291
Sci Rep. 2016 Jun 02;6:27198
pubmed: 27250901
Cell Growth Differ. 1999 Jul;10(7):473-8
pubmed: 10437915
Int J Cancer. 1996 Jun 21;69(3):190-2
pubmed: 8682586
Clin Cancer Res. 2000 Jun;6(6):2538-46
pubmed: 10873110
Br J Cancer. 1995 May;71(5):914-24
pubmed: 7537518
J Med Chem. 2014 Feb 27;57(4):1355-67
pubmed: 24450514
J Proteome Res. 2014 Nov 7;13(11):5250-61
pubmed: 25196676
Drug Resist Updat. 2015 Nov;23:20-54
pubmed: 26690339
Mol Med Rep. 2014 Oct;10(4):1927-34
pubmed: 25109431
Gynecol Oncol. 2012 Oct;127(1):241-8
pubmed: 22710073
Cancer Res. 1985 Oct;45(10):4970-9
pubmed: 3861241
Oncol Rep. 2006 Mar;15(3):621-7
pubmed: 16465422
Anticancer Drugs. 2004 Apr;15(4):371-6
pubmed: 15057142
Curr Drug Targets. 2001 Jun;2(2):135-66
pubmed: 11469716
Mol Pharmacol. 2001 Jul;60(1):174-82
pubmed: 11408612
Clin Cancer Res. 1999 Mar;5(3):643-54
pubmed: 10100718
Ann Oncol. 1991 Nov-Dec;2(10):751-4
pubmed: 1801881
Clin Cancer Res. 2009 Jan 1;15(1):9-14
pubmed: 19118027
Clin Cancer Res. 1999 Sep;5(9):2620-8
pubmed: 10499641
Proc Natl Acad Sci U S A. 1986 Dec;83(23):8923-5
pubmed: 3466165
J Clin Oncol. 2009 Jun 1;27(16):2686-91
pubmed: 19332726
Nat Rev Cancer. 2015 Nov;15(11):668-79
pubmed: 26493647
Proc Natl Acad Sci U S A. 1983 Sep;80(18):5573-7
pubmed: 6577444
Cancer Res Treat. 2008 Sep;40(3):106-10
pubmed: 19688115
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
BMC Cancer. 2005 Aug 04;5:95
pubmed: 16080796
Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2528-33
pubmed: 23359685
Cancer Commun. 1991 Mar;3(3):93-102
pubmed: 2001331
Biochem Pharmacol. 1988 Dec 15;37(24):4597-600
pubmed: 3144285
Cancer Invest. 1991;9(1):27-33
pubmed: 2012994
Cancer. 1997 Jul 1;80(1):1-7
pubmed: 9210702
Mol Biol Rep. 2013 Jan;40(1):1-6
pubmed: 23135731
Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):E542-9
pubmed: 21795601
J Cell Mol Med. 2015 Jul;19(7):1569-81
pubmed: 25689483
Gynecol Oncol. 2010 May;117(2):202-10
pubmed: 20031193
Br J Cancer. 2007 Mar 12;96(5):769-75
pubmed: 17339891
PLoS One. 2011 Feb 18;6(2):e16694
pubmed: 21364753
J Clin Oncol. 1998 Sep;16(9):2943-52
pubmed: 9738562
Nat Rev Cancer. 2003 May;3(5):330-8
pubmed: 12724731
J Control Release. 2015 May 28;206:67-74
pubmed: 25770398
Biochim Biophys Acta. 2012 Mar;1823(3):767-73
pubmed: 21878357
Pharm Res. 2018 Sep 12;35(11):206
pubmed: 30209680
Cancer Res. 1985 Dec;45(12 Pt 1):6250-3
pubmed: 4063975
Biochim Biophys Acta. 2002 Jul 18;1587(2-3):194-205
pubmed: 12084461
Mol Pharmacol. 1993 Apr;43(4):527-33
pubmed: 8474431
Colloids Surf B Biointerfaces. 2015 Dec 1;136:346-54
pubmed: 26433347
Cancer Chemother Pharmacol. 1993;32(3):167-72
pubmed: 8500219
Cancer Cell. 2004 Apr;5(4):341-51
pubmed: 15093541
Proc Natl Acad Sci U S A. 1988 Feb;85(3):650-3
pubmed: 3422447
Front Pharmacol. 2018 May 08;9:454
pubmed: 29867465
Mol Cancer Ther. 2012 Mar;11(3):616-28
pubmed: 22172489
Nat Rev Clin Oncol. 2014 May;11(5):282-98
pubmed: 24732946
Clin Cancer Res. 1998 Feb;4(2):469-73
pubmed: 9516938
Mol Cell Biol. 1999 Feb;19(2):1582-94
pubmed: 9891091
Mol Pharmacol. 2001 Mar;59(3):446-52
pubmed: 11179438
Mol Cell Biol. 1995 Jan;15(1):179-85
pubmed: 7799924
PLoS One. 2008 Jul 16;3(7):e2722
pubmed: 18628958

Auteurs

Gaetano Marverti (G)

Department of Biomedical, Metabolic and Neural Sciences, Via G. Campi 287, University of Modena and Reggio Emilia, 41125 Modena, Italy.

Gaia Gozzi (G)

Department of Biomedical, Metabolic and Neural Sciences, Via G. Campi 287, University of Modena and Reggio Emilia, 41125 Modena, Italy.

Eleonora Maretti (E)

Department of Life Sciences, Via G. Campi 213/d, University of Modena and Reggio Emilia, 41125 Modena, Italy.

Angela Lauriola (A)

Department of Biomedical, Metabolic and Neural Sciences, Via G. Campi 287, University of Modena and Reggio Emilia, 41125 Modena, Italy.

Leda Severi (L)

Department of Life Sciences, Via G. Campi 213/d, University of Modena and Reggio Emilia, 41125 Modena, Italy.

Francesca Sacchetti (F)

Department of Life Sciences, Via G. Campi 213/d, University of Modena and Reggio Emilia, 41125 Modena, Italy.

Lorena Losi (L)

Department of Life Sciences, Via G. Campi 213/d, University of Modena and Reggio Emilia, 41125 Modena, Italy.

Salvatore Pacifico (S)

Department of Chemical and Pharmaceutical Sciences, via Fossato di Mortara 17-19, University of Ferrara, 44100 Ferrara, Italy.

Stefania Ferrari (S)

Department of Life Sciences, Via G. Campi 213/d, University of Modena and Reggio Emilia, 41125 Modena, Italy.

Glauco Ponterini (G)

Department of Life Sciences, Via G. Campi 213/d, University of Modena and Reggio Emilia, 41125 Modena, Italy.

Eliana Leo (E)

Department of Life Sciences, Via G. Campi 213/d, University of Modena and Reggio Emilia, 41125 Modena, Italy.

Maria Paola Costi (MP)

Department of Life Sciences, Via G. Campi 213/d, University of Modena and Reggio Emilia, 41125 Modena, Italy.

Domenico D'Arca (D)

Department of Biomedical, Metabolic and Neural Sciences, Via G. Campi 287, University of Modena and Reggio Emilia, 41125 Modena, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH